Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 1, 2013

ViroPharma to terminate Phase II study of Cinryze

ViroPharma has decided to terminate the Phase II clinical evaluation of subcutaneous Cinryze (C1 Esterase Inhibitor [Human] with recombinant human hyaluronidase (rHuPH20)).

ViroPharma has decided to terminate the Phase II clinical evaluation of subcutaneous Cinryze (C1 Esterase Inhibitor [Human] with recombinant human hyaluronidase (rHuPH20)).

Cinryze is approved in the US as an intravenous administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).

"Cinryze is approved in the US as an intravenous administration for routine prophylaxis against angioedema attacks."

In Europe, Cinryze is approved for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks in adolescent and adult patients with HAE.

The decision, which followed a discussion with the Center for Biologics Evaluation and Research division of the FDA, is a precautionary measure related to the emergence of an unpredicted incidence and titer of non-neutralizing anti-rHuPH20 antibodies in a number of study patients.

However, antibodies with unknown clinical significance are not linked to any adverse clinical effects, according to the company.

In the fully enrolled study, around 41 patients completed at least one dosing arm of the study drug, with a total of 20 patients having completed both dosing arms.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The data from the study is expected to be informative for design of future subcutaneous administration studies.

Meanwhile, the company has developed an optimised, low-volume subcutaneous formulation of Cinryze and expects to conduct a Phase III subcutaneous registration study with the alternative formulation in the similar time frame anticipated for the combination product.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU